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Abstract
Background: There is strong mechanistic evidence to suggest that vitamin D and omega-3 long chain polyunsaturated
fatty acids (n-3 LCPUFAs), specifically docosahexaenoic acid (DHA), have the potential to significantly improve
the symptoms of autism spectrum disorder (ASD). However, there are no trials that have measured the effect
of both vitamin D and n-3 LCPUFA supplementation on autism severity symptoms. The objective of this 2 × 2
factorial trial is to investigate the effect of vitamin D, n-3 LCPUFAs or a combination of both on core symptoms of ASD.
Methods/design: Children with ASD living in New Zealand (n = 168 children) will be randomised to one of four
treatments daily: vitamin D (2000 IU), n-3 LCPUFAs (722 mg DHA), vitamin D (2000 IU) + n-3 LCPUFAs (722 mg
DHA) or placebo for 12 months. All researchers, participants and their caregivers will be blinded until the data
analysis is completed, and randomisation of the active/placebo capsules and allocation will be fully concealed
from all mentioned parties. The primary outcome measures are the change in social-communicative functioning,
sensory processing issues and problem behaviours between baseline and 12 months. A secondary outcome measure is
the effect on gastrointestinal symptoms. Baseline data will be used to assess and correct basic nutritional deficiencies
prior to treatment allocation. For safety measures, serum 25-hydroxyvitamin D 25(OH)D and calcium will be monitored
at baseline, 6 and 12 months, and weekly compliance and gastrointestinal symptom diaries will be completed
by caregivers throughout the study period.
Discussion: To our knowledge there are no randomised controlled trials assessing the effects of both vitamin
D and DHA supplementation on core symptoms of ASD. If it is shown that either vitamin D, DHA or both
are effective, the trial would reveal a non-invasive approach to managing ASD symptoms.
Trial registration: Australian New Zealand Clinical Trial Registry, ACTRN12615000144516. Registered on 16
February 2015.
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Background
Autism spectrum disorder (ASD) is a neurodevelopmental
disorder usually diagnosed when developmental, educa-
tional and social demands increase [1]. ASD is believed to
affect 1 % of the New Zealand population [1]. Diagnostic
criteria for ASD include delays or difficulties in socio-
communicative functioning, restricted and repetitive
behaviours/interests, sensory issues and aberrant be-
haviours [1, 2]. ASD is also associated with medical
conditions such as gastrointestinal problems [1–5].
The clinical symptoms of individuals with ASD vary
widely [5–7], suggesting that it is multi-factorial in nature.
It is generally agreed that both genetic and environ-
mental factors contribute to the development of ASD.
The high heritability of ASD has been shown by twin
and familial studies [8, 9]. However, it has been reported
that only 30 % of ASD cases are clearly associated with a
syndrome or genetic markers leaving the aetiology of
most cases without explanation [10].
Mechanistic evidence, as well as a scattering of eco-
logical and cross-sectional studies, suggests that vitamin
D may play an important role in the aetiology of ASD.
Vitamin D receptors and 1α-hydroxylase have been
identified in different regions of the brain and sensing
neurons [11–13]. The active form of vitamin D has been
shown to have an important role in the neuronal differ-
entiation, structure, function and connectivity of the de-
veloping brain [14]. Vitamin D response elements have
been identified on genes involved in serotonin and oxy-
tocin synthesis [15]. Lower levels of plasma oxytocin
[16] and abnormal serotonin concentrations in the brain
and tissues outside the blood–brain barrier have been
shown in populations with ASD [17, 18]. Oxytocin and
serotonin have been implicated in modulating social be-
haviour [19, 20].
The serum level of 25-hydroxyvitamin D (25(OH)D),
the best available marker of vitamin D status [21, 22],
has been shown to be significantly lower in autistic indi-
viduals than in their healthy counterparts [23, 24]. Simi-
larly, higher prevalence of ASD has been reported at
higher latitudes and in individuals exposed to lower
UVB radiation levels [24, 25]. In adults with severe
autism living in a community centre in Italy, problem
behaviours significantly increased during spring and de-
creased during autumn [26]. Depletion of vitamin D in
body stores by the end of winter and early spring sea-
sons (due to lack of sun exposure) may have exacerbated
the symptoms of autism and increased problem behav-
iours observed in this study.
The potential role of vitamin D deficiency in autism
has received surprisingly little attention. While a few
case studies have reported beneficial effects of vitamin
D supplementation on autistic core symptoms [27],
no randomised, placebo-controlled trial with vitamin
D supplementation has been conducted to date [28].
Jia et al. [27] reported that shifting serum 25(OH)D
concentration in a child with ASD from 31 to
203 nmol/L after 2 months of high-dose vitamin D
supplementation (150,000 international units (IU) per
month administered intramuscularly plus 400 IU per
day administered orally) improved autistic core symp-
toms. Although other trials investigating the effect of
multivitamin/mineral supplements containing low doses
of vitamin D on autism symptoms have provided promis-
ing results [29, 30], the individual effect of each nutrient
cannot be determined from these studies.
Omega-3 long chain polyunsaturated fatty acids (n-3
LCPUFAs) also have the potential to positively affect
children with ASD. These n-3 LCPUFAs, mainly DHA,
are necessary for normal development and functioning
of the brain and auditory and visual processing system
[31–33]. Long-term DHA depletion results in significant
losses in brain DHA with consequent loss of brain func-
tion [34]. Evidence shows that children with ASD have
an increased omega-6 to omega-3 ratio in blood and low
blood concentrations of n-3 LCPUFAs, which could be
due to either low dietary intake or differences in fatty
acid metabolism and incorporation into cellular mem-
branes of children with ASD [35–37].
Reports on the benefits of n-3 LCPUFAs in treating
ASD are inconclusive. There are, to our knowledge, only
four randomised, placebo-controlled trials [38–41], three
of which are small pilot studies. Bent et al. [40] and
Amminger et al. [39] found that omega-3 supplementa-
tion was superior over a placebo (12 and 6 weeks, re-
spectively) for reducing symptoms of hyperactivity and
stereotypic behaviour in children with ASD. However,
more recent studies have found that supplementation
with n-3 LCPUFAs for 6 months had no beneficial effect
on core symptom domains of ASD in children aged 2 to
5 years (n = 38) [41] and 3 to 10 years (n = 48) [38].
However, these studies are limited by their low partici-
pant numbers and short treatment periods.
In addition to these studies on the nutrients’ effects
when given individually, there are speculations that
vitamin D and n-3 LCPUFAs may improve ASD
symptoms because of their shared functions and each
nutrient-specific role that complements the other nu-
trient’s functions [42, 43]. Both nutrients are powerful
anti-inflammatory agents, immune modulators and
neuroprotectors [42]. Furthermore, evidence suggests
that while vitamin D regulates serotonin synthesis,
omega-3 fatty acids increase serotonin release and
membrane fluidity and thus increase serotonin acces-
sibility [43]. ASD is associated with increased inflam-
mation, oxidative stress, immune dysregulation and/or
mitochondrial dysfunction in brain regions that are
involved in social behaviour, sensory and motor
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coordination, memory, speech and auditory processing,
and also with neurotransmitter dysregulation [17, 18, 44].
Gastrointestinal problems have also been reported to
be common in children with ASD. Compared to their
typically developing siblings (12 %), autistic children
have more gastrointestinal symptoms (42 %) [3–5].
Gastrointestinal problems may relate to abnormal gut
flora [45], decreased activity of digestive enzymes [46] or
increased intestinal permeability [47]. Vitamin D defi-
ciency has been implicated in the pathophysiology of
some gastrointestinal diseases, including inflammatory
bowel disease [48], and thus might play a role in
ASD-related gastrointestinal problems. Likewise, n-3
LCPUFAs have been shown to reduce symptoms of
ulcerative colitis [49], to support epithelial integrity
in vitro [50], and to alter the gut microbiota compos-
ition of both neurodevelopmentally normal and early
life-stressed animals [51].
Unusual eating habits, a risk factor for nutrient defi-
ciencies, are common in ASD [4]. Inadequate intakes of
magnesium, zinc, folate, vitamins A, E, B12, K and D, as
well as low intake of foods rich in n-3 LCPUFAs, have
been reported in children with autism [52–58]. How-
ever, a broad picture of the nutritional status of affected
children in New Zealand is lacking.
Hypotheses
1. Both vitamin D and omega-3 status, defined as
omega-3 index (red blood cell (RBC) DHA +
eicosapentaenoic acid (EPA)), will be low in children
with ASD at baseline (25(OH)D <75 nmol/L [59] and
omega-3 index of approximately 4–6 % [60, 61])
2. Improving either vitamin D or omega-3 status with
supplementation will reduce the severity of ASD
symptoms in children with ASD
3. Combined vitamin D and n-3 LCPUFA supplemen-
tation will be more effective than either supplement
alone or placebo in reducing the severity of ASD
symptoms in children with ASD
Aims
1. To establish the vitamin D and RBC fatty acid status of
children with ASD living in Auckland, New Zealand
2. To investigate the effect of improving either vitamin
D or omega-3 status in reducing the symptoms of
ASD including sociocommunicative functioning,
sensory issues and aberrant behaviours (primary
outcomes) and gastrointestinal symptoms
(secondary outcome)
3. To establish the effectiveness of supplementation
with combined vitamin D and n-3 LCPUFAs in
reducing the symptoms of ASD including
sociocommunicative functioning, sensory issues and
aberrant behaviours (primary outcomes) and gastro-
intestinal symptoms (secondary outcome)
Methods/design
This study consists of two stages: stage 1 will include
recruitment and screening, while stage 2 is a vitamin
D and n-3 LCPUFA randomised, double-blind,
placebo-controlled trial (Fig. 1). The duration of the
intervention is 12 months.
Stage 1 will provide the opportunity for a compre-
hensive description of the study population with re-
spect to nutritional status (biochemical indices and
dietary intake), demographics and medical history.
Stage 2 will demonstrate the efficacy of supplementa-
tion with vitamin D, n-3 LCPUFAs or both on redu-
cing ASD symptoms.
Participants
This study is a collaboration between Massey University
and the Waitemata District Health Board (WDHB), New
Zealand. Caregivers of children who meet the criteria for
the study will be approached in the first instance by the
WDHB Developmental Coordinators.
We calculated that 42 participants (a minimum of
34 participants, and allowing for a 20-% potential
dropout rate) would be required for each arm of the
trial to demonstrate a clinically significant difference
at 80 % power and 5 % statistical significance. Power
calculations were based on a 17-unit difference be-
tween supplemented groups and placebo in change
from baseline to endpoint on the Social Responsive-
ness Scale (SRS) total score [62], on a mean SRS and
standard deviation of 105 and 24.7 units in untreated
children with ASD, respectively (from our 2015 pilot
study, unpublished). The sample size was calculated
using the formula below [63]:
N ¼ 2α2K= μ2‐μ1ð Þ2
where N is the sample size required per group, α is the
SD, K is the constant (7.9 denotes 80 % power and 5 %
significance), and (μ2 − μ1) is the difference in SRS total
score between groups.
To ensure that the study is adequately powered, a
blinded interim analysis at >50 % of the initially planned
enrolment will be performed by an independent third
party to estimate the variance for potential sample size
increase.
Inclusion and exclusion criteria
Children will be eligible for this study if they are aged
between 2.5 and 8 years, have a medical diagnosis of
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ASD confirmed by both a developmental paediatrician
in accordance with the criteria listed in the Diagnostic
and Statistical Manual of Mental Disorders, version
five (DSM-5) [2], and onset of symptoms after
18 months of age. The lower limit of 2.5 years has
been chosen based on the age criteria of the psycho-
logical assessment tools, and the upper limit of 8 years
has been chosen to avoid the confounding effect of
behavioural changes associated with pubertal stage.
The caregiver’s proficiency in English is a requirement
(due to the nature of outcome assessment tools). Vol-
unteers are excluded if they were diagnosed as having
developmental delay since birth.
Additional inclusion criteria for the trial are: liver
function within the normal range (albumin 34–48 g/L)
and serum 25(OH)D <75 + 10 nmol/L if they enter
the trial in winter and <105 nmol/L + 10 nmol/L if
they enter the trial in summer. A 10-nmol/L variation
was chosen because of the potential assay variability
[64]. We have applied two different cut-off points for
Fig. 1 Schematic diagram of study design. 1Blood biomarkers: 25-hydroxyvitamin D (25(OH)D), red blood cell (RBC) fatty acids, calcium, albumin,
iron studies, vitamin B12, folate, full blood count and vitamin A. Questionnaires: sociodemographics, medical history, eating/mealtime behaviours
and food diary. 2Questionnaires: sociocommunicative functioning, sensory problems and aberrant behaviours (primary outcomes); gastrointestinal
symptoms (secondary outcome), sun exposure and skin colour. Anthropometry: weight and height. 3Blood biomarkers: 25(OH)D, RBC fatty acids,
calcium and albumin. Questionnaires: sociocommunicative functioning, sensory problems, aberrant behaviours (primary outcomes) and eating/
mealtime behaviours and diet quality. Anthropometry: weight and height. 4Blood biomarkers: 25(OH)D, calcium and albumin. *Gastrointestinal
symptoms (secondary outcome) and medication/supplement use/incidence of adverse events/supplement compliance will be monitored
throughout the study period
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exclusion because there is a large seasonal variation
in serum 25(OH)D concentrations in New Zealand
ranging from 30 nmol/L [65] to 44 nmol/L [66].
Setting
The study will take place in Auckland, New Zealand.
Non-fasted blood samples will be collected at the North
Shore or Waitakere Hospitals in Auckland, New Zealand.
Questionnaires and anthropometry will be undertaken at
Massey University, Auckland, New Zealand. Auckland is
New Zealand’s largest city with a population of just over
one million. It has been estimated that approximately
13,000 (32.5 %) individuals with ASD reside in the Greater
Auckland region [1].
Stage 1 – screening
Screening and recruitment (stage 1 of the study) will
take place over a 24-month period, which commenced
in January 2015. Children who meet the initial inclusion
criteria will have a blood draw and will be screened for
nutritional deficiencies. See Tables 1 and 2 for outcome
measures, testing methods, and schedule of enrolment,
intervention, and assessment, respectively.
Pre-intervention preparation
Prior to randomisation and inclusion in the trial, vitamin
D, iron and vitamin B12 deficiencies will be addressed.
Refer to Table 3 for a list of nutritional deficiencies and
the management strategies applied in this trial.
Stage 2 – vitamin D and n-3 LCPUFA intervention
The intervention consists of 2000 IU of vitamin D3
per day, 722 mg of DHA per day, 2000 IU of vitamin
D3 plus 722 mg of DHA per day or placebo, in the
form of four oral capsules. The treatment materials
will be delivered in 750-mg gel capsules with a tear-off
nozzle manufactured and supplied by Douglas Nutrition
Ltd., Auckland, New Zealand. The study capsules, vitamin
D, n-3 LCPUFAs and placebo are identical in appearance
and all are tasteless and colourless. The child is required
to consume the contents of four capsules per day mixed
into their food of preference or by oral administration by
syringe. Refer to Table 4 for the total daily intake and con-
tents of each capsule. Throughout the study period, chil-
dren are allowed to have any therapy or medication for
autism as well as any supplement provided that it does
not contain vitamin D or omega-3.
Supplementation with 2000 IU vitamin D3 has been
shown to be a safe dose in infants [67, 68], and the
French Society of Paediatrics recommends 1000 to
1200 IU per day in breast-fed infants [69]. The body
mass of 2.5–8 year-olds in our trial will be considerably
greater than infants’, which should further reduce the
risk of adverse events. Furthermore, 2000 IU per day is
less than the safe upper limit of 2500 and 3000 IU/day
suggested by the IOM for 1–3 and 4–8 year age groups,
respectively [70].
The DHA dose of 722 mg/day is physiologically rele-
vant and achievable through diet (equivalent to approxi-
mately three servings of fatty fish per week) and is
comparable to doses used in other trials in children in-
vestigating the effects of n-3 LCPUFAs on behaviour
and learning [71]. No side-effects have been reported in
children with a dose of 600 mg DHA/day [72].
Randomisation, blinding and concealed allocation
Children will be randomly allocated to one of four
groups, having been stratified for age and severity of
ASD. Randomisation of the active/placebo capsules, the
randomised sequence list, and group assignment will be
fully concealed from the researchers, children and care-
givers for the entire study, including the data analysis. A
third party not involved in any aspects of the study will
generate a random block design in blocks of four and
eight using Randomization.com (http://www.randomiza-
tion.com/). The third party will allocate a treatment code
to a child once their eligibility for the intervention is
confirmed and the caregiver’s consent is received. In an
emergency situation where breaking of the study blind
will be required, plans will be in place for the principal
investigator to contact the third party responsible for
randomisation to reveal the treatment assignment for a
given participant.
Data collection
Participants (caregivers and children) will attend the
Human Nutrition Research Unit (HNRU) at Massey
University on two occasions: baseline and 12 months.
Once recruited into stage 2 and prior to being given a 4-
month supply of supplements, caregivers will complete
some questionnaires on core symptoms of ASD (socio-
communicative functioning and sensory issues) and aber-
rant behaviours as the study primary outcome measures,
and on gastrointestinal symptoms as the secondary out-
come measure. Once the intervention is completed
(12 months), baseline assessments of core symptoms of
ASD and aberrant behaviours completed by caregivers will
be repeated. Caregivers will also complete weekly gastro-
intestinal symptom diaries over the study period.
Further information will be collected to describe the
study population characteristics at the baseline. This in-
formation includes eating/mealtime behaviours, food
diaries, sun exposure, skin colour and anthropometry
(weight and height). At the final visit, baseline assess-
ment of eating/mealtime behaviours will be repeated and
children’s weight/height will be measured. Refer to
Table 1 for outcome measures and testing methods.
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Blood sampling and analysis
Children will have their blood samples drawn on three
occasions, baseline (stage 1 – screening), 6 months
(safety measures) and 12 months (endpoint). Refer to
Table 1 for nutritional biomarkers and testing methods.
The non-fasted blood samples will be collected under
the supervision of paediatric staff and processed at
North Shore or Waitakere Hospitals of WDHB labora-
tory service. Nutritional biomarkers will be assayed from
a venous blood sample. These include the following:
25(OH)D, RBC fatty acids, calcium, albumin, iron
studies, vitamin B12 and folate, full blood count and
vitamin A. With the exception of RBC fatty acids and
vitamin A, all biomarkers will be analysed at North
Shore Hospital. RBC fatty acids will be analysed at
the University of Wollongong, NSW, Australia, and
vitamin A in a laboratory at Massey University, Auckland,
New Zealand.
Questionnaires
The primary outcome measures are psychological assess-
ments of core symptoms of ASD and co-occurring prob-
lem behaviours which are detailed in Table 1. The
secondary outcome measure is the assessment of gastro-
intestinal problems. Standardised instructions will be
given to all caregivers on how to complete the question-
naires during their visit to the HNRU. Before the partici-
pant departs the HNRU researchers check all answers
for completeness.
Social Responsiveness Scale™, Second Edition (SRS-2)
[73]: the SRS-2 versions specific for age groups 2.5–4.5
Table 1 Summary of the study outcome measures and
methods
Variables Methods
Blood analysisa
25(OH)D Serum: Siemens ADVIA Centaur
Vitamin D Total assay
RBC fatty acids Erythrocytes: Shimadzu GC-17A
flame-ionisation gas chromatog
raphy (Rydalmere, NSW, Australia)
Calcium Serum: Siemens Dimension Vista®
System. CA Flex® reagent cartridge,
Cat. No. K1023
Albumin Serum: Siemens Dimension Vista®
System. ALB Flex® reagent cartridge,
Cat. No. K1013
Iron studies Ferritin, serum: Siemens Dimension
Vista® System. FERR Flex® reagent
cartridge, Cat. No. K6440
Iron, serum: Siemens Dimension
Vista® System. IRON Flex® reagent
cartridge, Cat. No. K3085
Total iron binding capacity, serum:
Siemens Dimension Vista® System.
TIBC Flex® reagent cartridge, Cat. No.
K3084
Vitamin B12 Serum: Siemens Dimension Vista®
System. B12 Flex® reagent cartridge,
Cat. No. K6442
Folate Serum: Siemens Dimension Vista®
System. FOL Flex® reagent cartridge,
Cat. No. K6444
Full blood count Whole blood: Sysmex XE-5000™
Automated Haematology System
Vitamin A Plasma:, Shimadzu Prominence
Modular HPLC System. Cat. No.
LC-20A. The assay was developed
at Massey University
Questionnaires
Primary outcome measures
Sociocommunicative
functioning
Social Responsiveness Scale-second
edition (SRS-2) [73]. Completed by
caregiver at Massey University
Sensory problems Sensory Processing Measure (SPM)
[75]. Completed by caregiver at
Massey University
Problem behaviours Aberrant Behaviour Checklist-
Community (ABC-C) [78]. Completed
by caregiver at Massey University
Secondary outcome measure
Gastrointestinal symptoms A questionnaire and diaries
completed by caregiver
Other measures
Sociodemographics Completed by caregiver
Medical history Completed by caregiver
Dietary assessments Dietary Index Children’s Eating
(DICE). Completed by caregiver
Table 1 Summary of the study outcome measures and
methods (Continued)
Feeding issues and mealtime
behaviours (Behavioural Paediatrics
Feeding Assessment Scale, BPFAS).
Completed by caregiver
Four-day estimated food diary.
Completed by caregiver. Analysed
using FoodWorks 2007 (Xyris
Software)
Nutritional supplements and
special dietary regimens.
Completed by caregiver
Sun exposure and skin
colour
Completed by caregiver
Medication/supplement use/
incidence of adverse events
and supplement compliance
Diary completed by caregiver
Anthropometry Weight: Tanita electronic scale;
Height: Stadiometre; measured by
researcher at Massey University
25(OH)D 25-hydroxyvitamin D, HPLC high-performance liquid chromatography,
RBC red blood cell
aAll blood samples are collected and analysed at the North Shore and
Waitakere Hospitals
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and 4.5 through 18 years will be used. SRS-2 identifies
social impairment associated with ASDs and quantifies
its severity in the domains of social awareness, social in-
formation processing, reciprocal social communication,
social anxiety/avoidance, and stereotypic behaviour/re-
stricted interests [73]. The clinical validity and sensi-
tivity of SRS-2 has been determined in populations
with ASD [74].
Table 2 Schedule of enrolment, intervention, and assessment
Study period
Enrolment Allocation Post allocation
Timepoint t−2 t−1 t0 tbaseline t6-month t12-month w1–52
Enrolment:
Initial eligibility screen ♦
Informed consent ♦
Nutritional deficiencies screen ♦
Allocation ♦
Interventions:
Vitamin D ♦ ♦ ♦
Omega-3 LCPUFAs ♦ ♦ ♦
Vitamin D + omega-3 LCPUFAs ♦ ♦ ♦
Placebo ♦ ♦ ♦
Assessments:
Nutritional biomarkers
Serum 25(OH)D ♦ ♦ ♦
RBC fatty acids ♦ ♦
Calcium ♦ ♦ ♦
Albumin ♦ ♦ ♦
Iron studies ♦
Vitamin B12 ♦
Folate ♦
Full blood count ♦
Vitamin A ♦
Primary outcome
Social Responsiveness Scale-2 ♦ ♦
Sensory Processing Measure ♦ ♦
Aberrant Behaviour Checklist ♦ ♦
Secondary outcome
Gastrointestinal symptoms ♦ ♦ ♦
Dietary assessment
Dietary Index Children’s Eating ♦ ♦
Behavioural Paediatric Feeding Assessment Scale ♦ ♦
4-day food diary ♦
Nutritional supplements and dietary regimen ♦
Other assessments
Sociodemographics ♦
Medical history ♦
Sun exposure and skin colour ♦
Compliance and adverse events diary ♦
25(OH)D 25-hydroxyvitamin D, t timeline, w week, LCPUFA long chain polyunsaturated fatty acid
According to the SPIRIT statement: Defining Standard Protocol Items for Clinical Trials
Mazahery et al. Trials  (2016) 17:295 Page 7 of 13
Sensory Processing Measures™ (SPM) [75]: the SPM
versions specific for age groups 2–5 and 5–12 years will
be used. SPM assesses sensory processing, planning and
ideas (praxis) and social participation in children. The
scales measure social participation, vision, hearing,
touch, body awareness (proprioception), balance and
motion (vestibular function) and planning and ideas
(praxis) [75]. This tool has been standardised, validated
and used in children with ASD [76, 77].
Aberrant Behaviour Checklist (ABC) [78]: the ABC
measures the variety of behaviour problems, namely
irritability, social withdrawal, stereotypic behaviour,
hyperactivity and inappropriate speech [79]. It has
been validated in children with ASD [80] and has been
widely used in treatment outcome studies of ASD [40].
Gastrointestinal symptoms questionnaire: the gastro-
intestinal symptoms questionnaire is designed specific-
ally for this study and includes gastrointestinal signs and
symptoms most commonly reported in children with
ASD [81, 82]. Caregivers of study participants will be
provided with weekly online diaries and will be asked to
record if the child had constipation, diarrhoea, flatu-
lence, abdominal pain, vomiting/nausea, abdominal
distension, unexplained daytime irritability or/and
unexplained night-time awakening during the past
week, and if so how many times these occurred. The
gastrointestinal symptoms questionnaire has not been
validated, but includes questions on gastrointestinal
symptoms most widely reported in ASD populations,
or behaviours that might be a consequence of
gastrointestinal symptoms. We are not aware of a vali-
dated instrument for assessing gastrointestinal symptoms
in autistic children, and certainly not in New Zealand.
Dietary Index of Children’s Eating (DICE): the DICE is
a simple diet-quality assessment tool which has been de-
veloped by the research team, based on the New Zealand
Ministry of Health Food and Nutrition Guidelines for
Healthy Children and Young People [83]. This tool
has been validated in a cohort of New Zealand
healthy children aged 2 to 8 years (unpublished), and
will be validated in ASD children in this study against
the 4-day estimated food diary and biochemical markers.
Behavioural Paediatrics Feeding Assessment Scale
(BPFAS): the BPFAS is a simple assessment tool which
measures a child’s mealtime behaviour and parents’ atti-
tudes and behaviours. It is a 35-item scale questionnaire
comprising 25-likert scale (5 points) questions about
child behaviour and 10 dichotomous questions about
parents’ attitudes and behaviours. Cut-off scores for the
BPFAS have recently been established [84]. The BPFAS
is the most reliable parent-administered feeding ques-
tionnaire, with good internal validity and test-retest
reliability [85].
Four-day estimated food diary: dietary intake data will
be collected by a 4-day estimated food diary, including
one weekend day. Instructions on how to accurately
complete the food diary will be provided with the food
diary. Participants will be given a free-post, pre-
addressed envelope for the return of the booklet.
Average macro and micronutrient intake will be
Table 4 Total daily intake of vitamin D and omega-3 long chain polyunsaturated fatty acids (n-3 LCPUFAs) and the contents of each
capsule, vitamin D, n-3 LCPUFAs and placebo
Treatment groups Daily intake
Vitamin D 2 × 750-mg capsules of olive oil, 2 × 1000-IU capsules of vitamin D3 in medium-chain triglycerides (MCT),
alpha tocopherol
N-3 LCPUFAs 2 × 750-mg capsules of olive oil, 2 × high-DHA triglyceride fish oil capsules (total DHA dose = 722 mg/day),
alpha tocopherol
Vitamin D and n-3 LCPUFAs 2 × 1000-IU capsules of vitamin D3 in 750 mg MCT, 2 × high-DHA triglyceride fish oil capsules (total DHA
dose = 722 mg/day), alpha tocopherol
Placebo 750-mg capsules of olive oil plus alpha tocopherol (antioxidant)
DHA docosahexaenoic acid, MCT medium-chain triglycerides
Table 3 Nutritional deficiencies and their management strategies prior to entering the intervention trial
Nutritional deficiency Management
Vitamin D Participants with serum 25(OH)D concentrations <25 nmol/L will be offered supplementation of 400 IU per daya
Iron Children with iron deficiency will be offered iron supplements and postponed entry into the trial after 3 months.
Children will not be retested A child will be iron deficient when two of the following pools are abnormal: red cell
pool (haemoglobin <111 g/L, red blood cell distribution width >14 %), transport iron (iron saturation <16 %) and/
or storage iron (serum ferritin ≤15 μg/L)a. Criteria for treatment will be according to the New Zealand Ministry of
Health guidelinesb
Vitamin B12 Children with serum levels <110 pmol/L will be offered the option of prescribed supplements or dietary advice
to improve status
aNew Zealand Ministry of Health 2015 [83]
bRetrieved from https://www.starship.org.nz/for-health-professionals/starship-clinical-guidelines/i/iron-deficiency/on 5 March 2015
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assessed over four reported days using FoodWorks
Professional Edition 7 (Xryis Software, Brisbane, QLD,
Australia, 2012).
In the present study, a 4-day food diary was chosen
because of the high respondent burden and time-
consuming characteristics of longer food diaries such as
a 7-day food diary. Because of the high within-person
variation in nutrient intakes, it is recommended to rec-
ord dietary intakes over a longer period of time to have
a highly accurate estimate of intake. However, if a 4-day
food diary covers different days randomly, it can provide
accurate estimates of dietary intake [86].
Information regarding sun exposure and skin colour,
nutritional supplements and any special dietary regimens
followed will be collected by questionnaires specifically
designed for the purpose of the current study. The sun
exposure questionnaire includes a question on care-
giver’s beliefs and attitudes toward sun exposure as
well as questions on country and city of residency in
pregnancy, season of birth and child’s sensitivity to
temperature and light extremes.
Compliance to medication/adherence to study protocol
Caregivers will receive weekly emails containing a link
to the online compliance and gastrointestinal issues
diary and a tip/fact about autism and nutritional matters.
Caregivers will be contacted by telephone at 1, 3, 6 and
9 months for morale purposes and to encourage compli-
ance. Caregivers also will receive quarterly trial newslet-
ters. The newsletters will include an update on the
study, generic topics about ASD, a caregiver’s experience
in relation to that topic, and entertainments/competi-
tions for the study children.
New intervention materials will be sent out to par-
ticipants every 4 months and caregivers will be asked
to place the bottles from the previous months aside,
with any unused capsules in them, to be returned at
their next visit (6 or 12 months) at which stage un-
used capsules will be counted and recorded. Compli-
ance to treatment will be analysed by counting each
participant’s remaining supplements once they have
completed the intervention.
Adverse events
All participants will be recalled at 6 months for a
blood test to check for hypervitaminosis D (serum
25(OH)D >225 nmol/L) and hypercalcaemia (serum
Ca >2.7 mmol/L). Results will be checked by a third
party who is unblinded (but has no involvement in
analysis of results). The third party will de-identify
blood test results and send them to the trial paedia-
trician and senior investigator for review and recom-
mendation if the child’s serum 25(OH)D or calcium
level is above the safe upper limit. If 25(OH)D
concentrations are at or approaching 225 nmol/L, or
if hypercalcaemia is present, dose administration will
be adjusted.
Compliance and gastrointestinal symptom diaries will
be monitored on a weekly basis and all side effects will
be recorded in the adverse events log to keep a track of
the child’s general health and behavioural reactions. In
the case of any adverse events, the child’s health will be
monitored more closely for three to four consecutive
weeks, and if the adverse event persists, the reports will
be referred to the trial paediatrician and senior investiga-
tor for further investigation.
Dissemination of results
Following the receipt and analysis of the food diary and
the completion of the biochemical assays at screening,
each participant will receive a feedback form. Anthropo-
metric measurements and blood results (iron studies,
vitamin B12, folate and full blood count) will also be in-
cluded. Once recruitment into the trial is completed,
participants who have not proceeded into the trial will
receive notification of their vitamin D and RBC fatty
acid levels.
On completion of the trial, participants will be in-
formed of their baseline and end vitamin D and RBC
fatty acid status, and whether they were taking the active
or placebo dose. They will also receive a summary of
psychological assessment outcomes of SRS-2 and SPM.
Participants and other stakeholders (such as health
professionals, district health boards, primary health or-
ganisations, ASD support groups) will be given access to
the study’s findings. Results will be presented at scien-
tific conferences both nationally and internationally, pre-
pared for publication in peer-reviewed journals, and
circulated to the media.
Data handling and statistical analysis
Name and address details will be maintained in Micro-
soft Excel. Check boxes will record the progress of a
participant through the study. All other data will be en-
tered into a single Microsoft Excel spreadsheet with
participants identified only by their unique Subject
Number. Scorings of the questionnaires will be double-
checked by the psychologist and the researcher. All en-
tries will be double-checked by another member of the
research team. All documents will be stored safely
under confidential conditions and archived for 5 years.
Statistical analysis will be performed using IBM SPSS
version 21.0 (IBM Corp; released 2012. IBM SPSS Statis-
tics for Windows Version 21.0. Armonk, NY, USA). Be-
fore commencement of statistical analysis the data will
be cleaned and checked for coding errors. The data will
be checked for plausibility by randomly checking the ac-
curacy and completeness and verifying against source
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data. The variables will be tested for normality using
the Kolmogorov-Smirnov test, the Shapiro-Wilk test
and normality plots. Non-normally distributed data
will be transformed into approximate normal distribu-
tions by logarithmic transformations. The data will be
reported appropriately as mean (standard deviation)
for normally distributed data; transformed data will
be back-transformed from summary statistics into
geometric mean (95 % CI), non-normally distributed
data will be described as median (25th, 75th percen-
tiles) and categorical data as frequencies.
Baseline characteristics of participants will be com-
pared among groups using analysis of variance
(ANOVA) for parametric data and the Kruskal-Wallis
test for non-parametric data. The primary analysis,
comparing the effects of treatment on symptoms of
autism over 12 months, will be conducted using a
generalised linear mixed-models procedure. Treat-
ments and time will be included as fixed effects and
the interactions between interventions and time will
be tested. If significant main effects or interaction ef-
fects are observed, post-hoc analysis with Bonferroni
adjustments will be performed. Potential confounding
factors and effect modifiers (e.g. baseline 25(OH)D
and RBC fatty acids, symptoms of autism at baseline,
age and gender) will be investigated within the model.
Logistic regression will be used to test the multiplicative
interaction. Rothman’s synergy index, which would be
equal to unity under additivity, and less than unity when
suggesting antagonism, will be utilised to examine the
postulated interaction effect of vitamin D and omega-3
LCPUFAs on core symptoms of ASD.
The secondary analysis, comparing the effects of treat-
ment on gastrointestinal symptoms over 12 months, will
be conducted using the same procedure. Potential con-
founding factors and effect modifiers (e.g. baseline diag-
nosis of any gastrointestinal symptoms and medication/
supplement use) will be investigated within the model.
Differences between participants who complete and
withdraw from the trial will be analysed using an inde-
pendent t test or the Mann–Whitney test for continuous
variables (e.g. age) and chi-square for categorical vari-
ables (e.g. gender).
Associations between severity of ASD symptoms and
nutritional status (specifically, vitamin D, RBC fatty
acids, iron and vitamin B12) at baseline will be assessed
using regression analysis. The information will be used
to assess treatment response according to tertiles of nu-
tritional status showing significant relationship with se-
verity of ASD.
Both intention-to-treat and per-protocol analyses will
be utilised, though the primary method of analysis will
be intention-to-treat. Statistical significance will be based
on two-tailed tests with P <0.05 considered significant.
Discussion
ASD is a life-long, disabling condition that is associ-
ated with deficits in social-communicative function-
ing, stereotypic behaviour and many behavioural and
medical conditions including gastrointestinal symp-
toms [1, 2, 5–7]. The main purpose of this study is
to measure the effect of vitamin D, n-3 LCPUFAs or
a combination of both on the symptoms of ASD in
affected children. There is a widespread interest in
the mechanistic role of vitamin D and n-3 LCPUFAs
in brain development and function, with some sup-
portive clinical and epidemiologic studies. However,
the effect of supplementing these nutrients on ASD
pathogenesis and progression is not known. We an-
ticipate that this trial will provide important insights
into this causality of reported associations. As far as
we are aware, no other randomised, double-blind,
placebo-controlled trial has investigated the effects of
vitamin D on symptoms of ASD, and the few trials
that have been conducted with n-3 LCPUFAs [38–41]
have been limited by small samples sizes and short
trial duration and have shown conflicting results.
The strength of this project lies in its design: part 1
has been designed to provide insight into the nutri-
tional status of children with ASD in New Zealand. Part
2 has been designed using a ‘Criterion Standard’ ap-
proach (randomised, double-blind, placebo-controlled
trial) to investigate the effect of supplementation. The
design minimises the effect of potential confounding
factors by correcting some nutritional deficiencies prior
to the trial entry and taking into account the effect of
confounders and covariates on ASD symptoms over
time. Our sample size and trial duration will also en-
sure an adequate power to detect clinically and statisti-
cally significant results.
If this trial is able to identify nutritional interven-
tions that can make even a small difference to the
lives of children with ASD by reducing their symp-
toms, the benefits will be considerable in terms of
social and emotional well-being and educational
achievements. Furthermore, it will also reduce the
emotional, physical and financial strains among fam-
ilies or caregivers of autistic children and the wider
societal networks. The potential benefits of the
current study go beyond New Zealand and will affect
all regions where ASD exists, and both vitamin D
and omega-3 status below the optimal level is highly
prevalent – the general trend of the most regions
worldwide.
Trial status
At the time of manuscript submission, the trial was
recruiting participants.
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